FDA approves subcutaneous Sarclisa Escena as first anticancer treatment administered via on-body injector – Sanofi
The FDA has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications of… read more.
